98%
921
2 minutes
20
Photodynamic therapy (PDT) holds great potential in cancer treatment, leveraging photosensitizers (PSs) to deliver targeted therapy. Fluorination can optimize the physicochemical and biological properties of PSs for better PDT performance. Here, we report some high-performance multifunctional PSs specifically designed for cancer PDT by fluorinating aza-BODIPY with perfluoro--butoxymethyl (PFBM) groups. Fluorination plays several roles, including enhancing selective cancer cell uptake, plasma membrane (PM) targeting, and inducing pyroptosis. It also enables fluorescence imaging (FLI) and fluorine-19 magnetic resonance imaging (F MRI) as well as facilitates oxygen delivery and oxygen partial pressure (pO) measurements. Comparative physicochemical and biological studies, along with molecular dynamics simulations, reveal that fluorinated PSs selectively eradicate cancer cells by oxidizing PM phospholipids with singlet oxygen (O) and inducing pyroptosis, which enables effectively suppressed tumor growth by self-oxygenated F MRI-FLI-guided PDT in mice. This study demonstrates a fluorination strategy for tailoring high-performance multifunctional cancer PM-targeting materials for cancer therapy and beyond.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11744507 | PMC |
http://dx.doi.org/10.1021/acsami.4c17943 | DOI Listing |
Curr Opin Microbiol
September 2025
Cryptosporidiosis Laboratory, The Francis Crick Institute, London, United Kingdom. Electronic address:
The movement of molecules across the membranous barriers of a cell is fundamental to cellular homeostasis in every living organism. This vital process is facilitated through a mechanistically diverse class of proteins, collectively known as membrane transporters. Among these are so-called carrier proteins that can function in passive and active transport mechanisms.
View Article and Find Full Text PDFBiomaterials
September 2025
Key Laboratory of Biopharmaceutical Preparation and Delivery, Institute of Process Engineering, Chinese Academy of Sciences, Beijing, 100190, PR China; University of Chinese Academy of Sciences, Beijing, 100049, PR China. Electronic address:
The stimulator of interferon genes (STING) pathway represents a promising target in cancer immunotherapy. However, the clinical translation of cyclic dinucleotide (CDN)-based STING agonists remains hindered by insufficient formation of functional CDN-STING complexes. This critical bottleneck arises from two interdependent barriers: inefficient cytosolic CDN delivery and tumor-specific STING silencing via DNA methyltransferase-mediated promoter hypermethylation.
View Article and Find Full Text PDFJCO Glob Oncol
May 2025
Grupo Oncoclínicas, São Paulo, Brazil.
Head and neck squamous cell carcinoma (HNSCC) represents a significant public health burden in developing countries, where access to early diagnosis, comprehensive care, and research infrastructure is limited. This article synthesizes the insights generated during a Fireside Chat convened by members of the Latin American Cooperative Oncology Group (LACOG)-Head and Neck and the Brazilian Group of Head and Neck Cancer (GBCP), with the participation of international expert Professor Hisham Mehanna. The discussion addressed key challenges and opportunities in clinical and translational research within resource-constrained settings.
View Article and Find Full Text PDFBiochem J
September 2025
Cancer Research UK Scotland Institute, Glasgow, G61 1BD, U.K.
RNA cap formation on RNA polymerase II transcripts is regulated by cellular signalling pathways during development and differentiation, adaptive and innate immune responses, during the cell cycle and in response to oncogene deregulation. Here, we discuss how the RNA cap methyltransferase, RNA guanine-7 methyltransferase (RNMT), functions to complete the 7-methyl-guanosine or m7G cap. The mechanisms by which RNMT is regulated by signalling pathways, co-factors and other enzymes are explored.
View Article and Find Full Text PDFBlood Adv
September 2025
AP-HP, Hôpital Saint Louis and University of Paris, INSERM U944 and THEMA insitute, Paris, France.
Germline DDX41 mutations (DDX41mut) are identified in approximately 5% of myeloid malignancies with excess of blasts, representing a distinct MDS/AML entity. The disease is associated with better outcomes compared to DDX41 wild-type (DDX41WT), but patients who do not undergo allogeneic hematopoietic stem cell transplantation (HSCT) may experience late relapse. Due to the recent identification of DDX41mut, data on post-HSCT outcomes remain limited.
View Article and Find Full Text PDF